Overview

Drugs Made In America Acquisition Corp. is a blank check company formed in May 2024 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company completed its initial public offering (IPO) in January 2025, raising $200 million by selling 20 million units at $10 per unit. Each unit consists of one ordinary share and one right to receive one-eighth of one ordinary share upon the consummation of an initial business combination.

Financial Performance

The company has not engaged in any operations or generated any revenue to date. Its only activities have been organizational, preparing for the IPO, and identifying a target company for an initial business combination. The company generates non-operating income in the form of interest earned on the cash and investments held in its trust account.

For the three and six months ended June 30, 2026, the company had net income of $1.7 million and $3.7 million, respectively. This consisted of $1.9 million and $4.0 million in interest income, offset by $0.1 million and $0.3 million in general and administrative costs.

For the three and six months ended June 30, 2025, the company had net income of $2.3 million and $3.5 million, respectively. This consisted of $2.4 million and $4.0 million in interest income, offset by $0.1 million and $0.5 million in general and administrative costs.

Liquidity and Capital Resources

As of June 30, 2026, the company had $20,280 in cash. Its main source of liquidity has been the proceeds from its IPO and private placement of units.

The company placed $231.2 million of the IPO and private placement proceeds into a trust account. It intends to use these funds, along with any interest earned, to complete an initial business combination. The company has incurred $8.9 million in transaction costs related to the IPO.

To fund working capital needs or transaction costs, the company’s sponsor or affiliates may provide loans, which could be convertible into units of the post-business combination entity.

Going Concern

The company’s pursuit of a business combination and the date for mandatory liquidation raise substantial doubt about its ability to continue as a going concern within one year. Management plans to address this uncertainty through a business combination, but there is no assurance they will be successful within the required timeframe.

Key Points

• Blank check company formed in 2024 to pursue a business combination
• Completed $200 million IPO in January 2025, raising funds held in trust account
• Generated net income of $1.7-$3.7 million in 2026 from interest on trust account
• Relying on sponsor loans and eventual business combination to fund operations
• Substantial doubt about ability to continue as going concern within one year

Overall, Drugs Made In America Acquisition Corp. is an early-stage company focused on identifying and completing a business combination, likely in the pharmaceutical industry. Its financial performance to date has been limited to interest income, while it continues to incur costs in pursuit of a deal. The company faces uncertainty about its ability to complete a transaction and continue as a going concern.